Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors

Cancer Biology and Therapy

Volumn 14, Issue 9, 2013, Pages 806-811

  Côté, Jérôme ^a,b   Savard, Martin ^a,b   Neugebauer, Witold ^a,b   Fortin, David ^a,b   Lepage, Martin ^a,b   Gobeil, Fernand ^a,b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Blood brain barrier; G protein coupled receptors; Glioma; Kinins; MRI; Rat; Synthetic agonists

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; GADOLINIUM PENTETATE; HETERODIMER; KININ; KININ B1 RECEPTOR; KININ B2 RECEPTOR; KININ B2 RECEPTOR AGONIST; OPIATE AGONIST; UNCLASSIFIED DRUG; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; CONTRAST MEDIUM;

AGONIST; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG POTENCY; DRUG TARGETING; GLIOMA; HUMAN; HUMAN CELL; IC 50; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; SURVIVAL RATE; TUMOR XENOGRAFT; AGONISTS; ANIMAL; BRAIN NEOPLASMS; CHEMISTRY; CLICK CHEMISTRY; DIMERIZATION; DRUG EFFECTS; DRUG POTENTIATION; FISCHER 344 RAT; HEK293 CELL LINE; METABOLISM; PERMEABILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CARBOPLATIN; CLICK CHEMISTRY; CONTRAST MEDIA; DIMERIZATION; DRUG SYNERGISM; GLIOMA; HEK293 CELLS; HUMANS; KININS; PERMEABILITY; RATS, INBRED F344; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2;

EID: 84883376947     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25327     Document Type: Article

References (16)

1. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004; 3:430-46; PMID:15136790; http://dx.doi.org/10.1038/nrd1380
2. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007; 25:2295-305; PMID:17538176; http://dx.doi.org/10.1200/ JCO.2006.09.9861
3. Fortin D. The blood-brain barrier: its influence in the treatment of brain tumors metastases. Curr Cancer Drug Targets 2012; 12:247-59; PMID:22229251; http://dx.doi.org/10.2174/156800912799277511
4. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003; 6:252-73; PMID:12935438
5. Black KL, Ningaraj NS. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 2004; 11:165-73; PMID:15153840
6. Côté J, Bovenzi V, Savard M, Dubuc C, Fortier A, Neugebauer W, et al. Induction of selective bloodtumor barrier permeability and macromolecular transport by a biostable kinin B1 receptor agonist in a glioma rat model. PLoS One 2012; 7:e37485; PMID:22629405; http://dx.doi.org/10.1371/ journal. pone.0037485
7. Côté J, Savard M, Bovenzi V, Dubuc C, Tremblay L, Tsanaclis AM, et al. Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study. Neuropeptides 2010; 44:177-85; PMID:20080302; http://dx.doi.org/10.1016/ j. npep.2009.12.009
8. Emerich DF, Dean RL, Snodgrass P, Lafreniere D, Agostino M, Wiens T, et al. Bradykinin modulation of tumor vasculature: II. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J Pharmacol Exp Ther 2001; 296:632-41; PMID:11160652
9. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3:319-28; PMID:12639809; http://dx.doi.org/10.1016/S1567-5769(02)00271-0
10. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 2005; 57:217-52; PMID:15914468; http://dx.doi.org/10.1124/pr.57.2.1
11. Bélanger S, Bovenzi V, Côté J, Neugebauer W, Amblard M, Martinez J, et al. Structure-Activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides 2009; 30:777-87; PMID:19111586; http://dx.doi.org/10.1016/j.peptides.2008.12.003
12. Savard M, Labonté J, Dubuc C, Neugebauer W, D'Orléans-Juste P, Gobeil F Jr. Further pharmacological evaluation of a novel synthetic peptide bradykinin B2 receptor agonist. Biol Chem 2013; 394:353-60; PMID:23362191; http://dx.doi.org/10.1515/hsz-2012-0295
13. Côté J, Savard M, Bovenzi V, Bélanger S, Morin J, Neugebauer W, et al. Novel kinin B1 receptor agonists with improved pharmacological profiles. Peptides 2009; 30:788-95; PMID:19150636; http://dx.doi.org/10.1016/j.peptides.2008.12.018
14. Gobeil F, Pheng LH, Badini I, Nguyen-Le XK, Pizard A, Rizzi A, et al. Receptors for kinins in the human isolated umbilical vein. Br J Pharmacol 1996; 118:289-94; PMID:8735629; http://dx.doi.org/10.1111/j.1476-5381.1996.tb15401.x
15. Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, et al. Strategies to advance translational research into brain barriers. Lancet Neurol 2008; 7:84-96; PMID:18093565; http://dx.doi.org/10.1016/ S1474-4422(07)70326-5
16. Zhao Y, Xue Y, Liu Y, Fu W, Jiang N, An P, et al. Study of correlation between expression of bradykinin B2 receptor and pathological grade in human gliomas. Br J Neurosurg 2005; 19:322-6; PMID:16455538; http:// dx.doi.org/10.1080/02688690500305555